ClinicalTrials.gg
RecruitingNCT02308917CIDsCaNNUpdated Oct 9, 2026

The Canadian Children Inflammatory Bowel Disease Network (CIDsCaNN)

An observational study in Inflammatory Bowel Diseases, Crohn's and Ulcerative Colitis, sponsored by The Hospital for Sick Children. Recruiting at 12 sites in Canada. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Primary conditionColitis, UlcerativeRegistry: Inflammatory Bowel DiseasesReclassifiedWhy we changed it
Registry
Inflammatory Bowel Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Colitis, Ulcerative
Why
  1. The study's listed conditions name Colitis, Ulcerative, a narrower term within Inflammatory Bowel Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by The Hospital for Sick Children · Observational

How we know

From the registry’s dates

  • Started Sep 2013; still recruiting 13 years 2 months later.
Updated Oct 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,400
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 265 studies in Colitis, Ulcerative with a site in Canada — 47 open to participants now, 84 under way, 24 of them phase 3. Colitis, Ulcerative · Canada.

Planned enrollment
6th of 38
2,400 · median 197
Started
2013
with 9 others
Observational
38 of 265
7 open now
Primary completion
2028-11
later than 71 of 83 live
Registered
65th of 265
by date

Among the 265 studies in Colitis, Ulcerative with a site in Canada, this one is the 6th largest by planned enrollment of the 38 observational ones that give a count, is one of 10 that started in 2013, is one of 38 observational ones, reaches primary completion later than 71 of the 83 other live ones, and was the 65th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

47 of the 265 studies in Colitis, Ulcerative with a site in Canada are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Colitis, Ulcerative with a site in Canada, or all of them as a file.
02

Study summary

The CIDsCaNN Network is being established with the major goals of identifying why IBD develops so commonly in children and adolescents living in Canada, and of determining the best treatment strategies for different types of IBD. Focusing on a prospective, inception cohort of Canadian children of widely varied racial origins provides a unique opportunity to explore environmental risk factors early in life and close in time to disease onset, their influence on the host microbiome, and in the context of genetic susceptibility. In keeping with current treatment targets, assessed outcomes will include not only symptom resolution and growth, but also intestinal healing. We aim to identify best practice and to institute processes for continual improvement in care nationally.

Read the detailed description

IBD is also known as Crohn's Disease or Ulcerative Colitis. Please read the definitions of each of these conditions below:

  1. Crohn's Disease: A condition that causes "inflammation" which is swelling, redness, soreness, in different parts of your intestines; either the large intestine only, the small intestine only or both.
  2. Ulcerative Colitis: A condition that causes "inflammation" which is swelling, redness and soreness in the lining of your large intestine (colon) only.

IBD may run in families, meaning that it can be passed down through genes. However, compared to other parts of the world, it has been found that the number of children with IBD living in Canada is higher. It has also been found that children whose families have come from parts of the world where IBD is not common, have the same chance of developing IBD as children born and raised in Canada. This seems particularly true for children, whose families have come here from South Asia. Because of this, doctors think that aside from genetic factors, there may be factors in the environment to explain why this has been observed.

At this time, the factors in the environment which can trigger the development of IBD are not well understood. By working together in the Network, physicians who treat IBD will be able to gain a better understanding of the environmental factors that contribute to the development of IBD.

We aim to enroll children and teenagers who have developed IBD and are being treated at participating Network centers in Canada with the goal of sharing biological samples, demographic and lifestyle information, disease history, and treatment outcomes.

Samples may be stored indefinitely so that, as additional genes, biomarkers, and microbes are discovered, their role in intestinal disease can be assessed. The importance of these samples increase over time as outcomes of intestinal disease and treatment may be tracked. As required in future, research studies proposing to use biobank data and/or samples will be submitted to a study committee and the REB (Research Ethics Board) for approval.

Approximately 2400 participants will be recruited to the Networks Inception Cohort study. They will be followed from recruitment until transfer to adult care.

The National Coordinating Centre Team and Organizational Structure

The Network's National Coordinating Centre is housed at The Hospital for Sick Children, University of Toronto. Information Technology infrastructure and support will be provided by the SickKids Research Institute's Research IT Department. Additional 'ad-hoc' resources related to IT development/support, legal counsel, bio-statistical assistance will be available to the centre as required via the resources of the SickKids Research Institute.

The National Coordinating Centre is responsible for data-integrity and completeness and ensures accountability by sites for full and timely data completeness. Support systems for collecting and recording data and encourages 'real-time' data abstraction and direct data entry. The Network is utilizing the REDCap (Research Electronic Data Capture) application as its primary data-collection platform. REDCap is a secure, web-based application designed to support data capture for research studies, providing: 1) an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data download to common statistical packages; and 4) procedures for importing data from external sources. Within the data collection platform, numerous 'real-time' and 'post hoc' data check procedures will be implemented. Statistics concerning 'data-integrity' will be reported to the Executive Committee on a regular and frequent basis. The National Coordinating Centre will conduct site-specific staff training at the initiation of the study, when new staff are employed, and when any new tools or significant study procedures are added to the protocol.

ORGANIZATION and GOVERNANCE of NETWORK

Preamble: During the next 5-year period, the Network Executive will aim to provide both the opportunity and governance to foster development of new leaders in pediatric IBD in Canada; continue to lead in pediatric IBD research; and initiate a plan for sustainability in leadership and research productivity/funding. Diversity in the broadest sense, inclusiveness and engagement will be core values for performance. Taken together, the proposed Network governance has been changed in the following ways:

  1. A plan for regular renewal of the 3-person Executive committee, which going forward will always consist of 2 co-chairs and a co-chair elect.
  2. A Steering Committee (composed of committee leads or co-leads and with two additional early career representatives) will be formed in which each committee will be responsible for specific academic areas and will develop a process for renewal of its leadership. The Steering Committee will meet on a monthly basis and report to the Executive committee to update progress in their areas of responsibility and the two bodies together will drive Network activities and plans.
  3. A more comprehensive, broader-ranging committee structure with clear responsibilities and deliverables.

1) 3-person Executive committee The 3-person executive committee is responsible for the overall directions, operation, and decisions of the Network. In a Network that aims to be sustainable, it is mandatory that there be a mechanism for renewal and revitalization of such leadership.

For the sake of continuity, heading into phase 2, the previous Chair (Griffiths) and one Co-chair (Mack) of the former Network Management Committee (NMC) will remain on the Executive Committee as Co-chairs. A nomination committee, consisting of Drs. David Mack, Anthony Otley, and Sally Lawrence, geographically representing respectively Central, Eastern and Western Canada, will establish a slate of candidates for the Co-chair elect position to be voted on by the Network membership in the context of the late fall annual meeting. Process for voting to be established at late August steering committee meeting.

In general, as the Network continues in the future, an elected incoming Co-chair elect, will serve on the Executive committee for 3 years (one year as co-chair Elect; two years as Co-chair), long enough to allow success in leadership, but short enough so that the opportunity for such leadership is open to the many qualified individuals within the Network, which will enrich the reach and impact of the Network efforts. As a new Chair-elect joins the 3-person executive committee, the longest serving Co-chair moves off, having in general served for 3 years.

The first co-chair Elect will join Drs Griffiths and Mack on the Executive committee in the late fall of 2021. Given the crucial period of the upcoming two years, this Executive committee will exceptionally remain in place until fall of 2023 (rather than 2022, as would happen in general). The delayed movement of Dr. Griffiths off the Executive committee and correspondingly delayed second election of a new member will mean that the 2021 co-chair elect will exceptionally serve in leadership for 4 years instead of the customary three years.

2) Steering committee Members of the Steering Committee are either committee Leads or (for larger committees) Co-Leads, with the exception that two positions are reserved for early career representatives (one representing Basic Research; one representing Clinical and Translational research). These are all named in Figure. The early career representatives, chosen based on their abilities, accomplishments and contributions to the Network to date, are affiliated with committees, but are not being given administrative responsibilities for committee leadership. It is anticipated that they will contribute meaningfully to Steering committee discussions in these roles, which have been developed as part of the Network's commitment to Training and Mentoring of the next generation of leaders.

At monthly joint meetings of the Steering and Executive committees, the expectations are 1) that committee leads will report on their activities and 2) all members together will discuss and make decisions about Network initiatives.

This change in governance structure is being made for four main reasons: 1) to allow more regular and more productive interactions between leaders with clinical investigative expertise and those with basic research expertise, given the phase 2 mandate to ensure optimal utilization of collected biospecimens, 2) to allow delegation of responsibilities with accountability, thereby aiming to increase transparency and productivity 3) to allow for greater engagement of Canadian pediatric IBD sub-specialists to find solutions for pediatric IBD, to further standardize care and 4) to foster development of new and emerging leaders.

3) Broader committee structure As shown in the Figure, the scope of committee involvement has increased from the time of Network initiation to now include Clinical care and research; Education; Patient engagement and advocacy; Training and Mentorship in addition to the prior (but somewhat renamed and refocused) Basic and Translational Research; Data management and integration; Health services research. Committees with larger portfolios will have co-leads, with shared responsibilities.

Basic and Translational research committee (BTRC): Co-Leads: Bruce Vallance and Eytan Wine Clinical care and research committee (CCRC): Co-leads, Hien Huynh and Wael El-Matary Data Management and Integration: Lead,: Thomas Walters Health Services Research: Lead, Eric Benchimol Training and Mentorship: Lead, Kevan Jacobson Education: Co-leads, Colette Deslandres and Sally Lawrence Patient engagement and advocacy: Lead, Anthony Otley

The Network remains primarily a Network for research aimed at enhancing clinical outcomes, be it development of disease prevention strategies or superior treatment paradigms. It is committed to encouraging individuals to drive specific questions using the infrastructure provided and drawing on a larger patient base than is available in individual centres. A robust data management platform with feedback of data to sites will support collection and utilization of biospecimens for basic research. Consent for linkage of data/samples to administrative health data will facilitate long-term follow-up.

An important improvement in Governance structure is the planned crosstalk between committees (e.g., ensuring mutual input between BTRC and CCRC projects), which will be achieved through the steering committee meetings as well as via co-membership in lead committees.

The addition of network-wide virtual educational initiatives over the past year has demonstrated that this is an effective way of engaging more physicians, researchers, and allied healthcare professionals in the Network. We anticipate that such interactive educational sessions will in turn 1) encourage greater engagement in prospective research and 2) provide a forum wherein data generated within the Network's studies will be shared, thereby stimulating further research and benefiting the clinical care of other patients nationally.

We anticipate that the Patient engagement and advocacy committee will have similar impact within the network.

03

Conditions studied

  • Inflammatory Bowel Diseases
  • Crohn's
  • Ulcerative Colitis

Browse trials for

Keywords

  • IBD-U
  • Crohn's
  • Ulcerative colitis
  • IBD
04

In context

Colitis, Ulcerative Reclassified

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

This study's planned enrollment of 2,400 is above the median of 199 across 552 observational studies indexed under Colitis, Ulcerative.

Browse Colitis, Ulcerative studies →

Lead sponsor

The Hospital for Sick Children is the lead sponsor of 579 studies on the registry; 81 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Compared within Colitis, Ulcerative, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammatory Bowel Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The network will enroll all children and adolescents diagnosed with IBD - Crohn's, Ulcerative Colitis or inflammatory bowel disease undefined (Paris A1a or A1b definitions of age at diagnosis) at participating sites.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosed with IBD - Crohn's, ulcerative colitis or inflammatory bowel disease undefined

Exclusion criteria

Exclusion Criteria:

  • Refusal to give
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,400 participants (estimated)
Target follow-up
144 Months
Patient registry
Yes
Biospecimen retention
Samples with dna
07

What researchers measure

Primary outcomes

  1. Sustained Clinical Remission

    Primary outcome: To test the research hypothesis, the primary endpoint is sustained clinical remission, as defined for CD by PCDAI \<10 and for UC as PUCAI \< 10 at each of the 6, 12, and 18 month visits AND physician global assessment of interval disease severity as quiescent at each of these visits. This primary endpoint will be assessed at 18 months, although it is the intent of the network to continue evaluations of the cohort until transfer to adult care.

    Time frame: 18 months after enrollment onto study

Secondary outcomes

  1. Other Clinical Outcomes (combination of Pediatric Crohn's Disease Activity Index, Pediatric Ulcerative Colitis Activity Index, physician global assessment of disease activity, serologic inflammatory markers and fecal calprotectin results)

    Initial treatment response will be assessed at 30 days using a combination of PCDAI (Pediatric Crohn's Disease Activity Index), PUCAI (Pediatric Ulcerative Colitis Activity Index), physician global assessment of disease activity, serologic inflammatory markers and fecal calprotectin results where applicable. Information from ongoing studies shows that 60% of patients are in a sustained clinical remission by 12 months. These results will identify the percentage of patients at achieve initial treatment response within 30 days.

    Time frame: 18 months after initial enrollment onto study

Other outcomes

  1. Assessment of Intestinal Healing

    Assessment of intestinal healing will be captured at Network Sites. Sites will be asked annually to record whether or not reassessment via endoscopy and/or MR imaging have/ has been performed and, if so, to record findings using the multi-item measures as at time of diagnosis. After 4 years of study initiation, the results will be analysed to ascertain whether including assessment using endoscopy and/or MR imaging is more accurate than assessing clinical symptoms and signs alone.

    Time frame: 18 months after initial enrollment onto study

08

Study locations

12 of 12 sites recruiting
  • Alberta Children'S Hospital
    Calgary, Alberta T3B 6A8, Canada
    Recruiting
  • Stollery Children'S Hospital
    Edmonton, Alberta T6G 2B7, Canada
    Recruiting
  • Children'S Hospital of Bc
    Vancouver, British Columbia V6H 3N1, Canada
    Recruiting
    • Kevan Jacobson, MD · Contactkjacobson@cw.bc.ca · 604-875-2332
    • Kevan Jacobson, MD · Principal investigator
  • Winnipeg Children'S Hospital
    Winnipeg, Manitoba R3E 3P4, Canada
    Recruiting
  • Janeway Children'S Health & Rehabilitation Centre
    St. John's, Newfoundland and Labrador A1B 3V6, Canada
    Recruiting
  • Izaak Walton Killam Hospital (Iwk)
    Halifax, Nova Scotia B3K 6R8, Canada
    Recruiting
  • Hamilton Health Sciences
    Hamilton, Ontario L8L8E7, Canada
    Recruiting
  • CHILDRENS HOSPITAL OF WESTERN ONTARIO, Lawson Health Research Institute
    London, Ontario N6C2R5, Canada
    Recruiting
  • Children's Hospital of Eastern Ontario (CHEO)
    Ottawa, Ontario K1H 8L1, Canada
    Recruiting
    • David Mack, MD · Contactdmack@cheo.on.ca · 613-737-7600
    • David Mack, MD · Principal investigator
  • SickKids Hospital
    Toronto, Ontario M5G 1X8, Canada
    Recruiting
  • Montreal Children'S Hospital
    Montreal, Quebec H3H 1P3, Canada
    Recruiting
    • Najma Ahmed, MD · Contactnajma.ahmed@mcgill.ca · 514-412-4474
    • Najma Ahmed, MD · Principal investigator
  • Hopital Ste. Justine
    Montreal, Quebec H3T 1C5, Canada
    Recruiting
09

References and documents

Publications

  • Klomberg RCW, Griffiths AM, Aloi M, Kiparissi F, Lawrence S, Otley AR, Critch J, van der Feen C, Rodrigues A, Mack DR, Huynh HQ, Church PC, Rizopoulos D, Croft NM, de Ridder L, Walters TD; European Paediatric IBD Network for Safety, Efficicacy of Treatment and Quality Improvement of Care (PIBD-SETQuality); Canadian Children IBD Network (CIDsCaNN). A comparative analysis of corticosteroids and exclusive enteral nutrition induction therapy in children with small bowel Crohn's disease: results of two prospective cohorts. Eur J Pediatr. 2026 May 19;185(6):413. doi: 10.1007/s00431-026-07061-8. PubMed 42154069 ↗
  • deBruyn JC, Huynh HQ, Griffiths AM, Jacobson K, Mack D, Deslandres C, El-Matary W, Otley AR, Church PC, Lawrence S, Wine E, Sherlock M, Critch J, Benchimol EI, Jantchou P, Rashid M, Carroll MW, Bax K, Ricciuto A, Carman N, Walters TD; and the Canadian Children IBD Network. Adalimumab vs Infliximab in Luminal Pediatric Crohn's Disease: Comparable Outcomes in a Prospective Multicenter Cohort Study. Am J Gastroenterol. 2024 Mar 1;119(3):565-575. doi: 10.14309/ajg.0000000000002552. Epub 2023 Oct 3. PubMed 37787642 ↗
10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2013 (actual). Primary completion is estimated for Nov 2028, 182 months after the start.

Of 188 non-industry observational studies under Colitis, Ulcerative, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 119. This study's planned 182 months is above that.

Counting every sponsor, half of 271 studies reached it within 47 months; a quarter within 29 and three quarters within 90.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Apr 2026 → Nov 2028 and completion Apr 2026 → Nov 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2013
First posted
Dec 5, 2014
StartActual
Sep 2013
Primary completionEst.
Nov 1, 2028was Apr 2026
CompletionEst.
Nov 1, 2028was Apr 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 1, 2026→Nov 1, 2028
Oct 9, 2026
Study completion
Apr 1, 2026→Nov 1, 2028
Oct 9, 2026
Publications
2 publications citing this study linked from PubMed, e.g. PubMed 42154069 ↗
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Publications 2 publications citing this study linked from PubMed, e.g. PubMed 42154069 ↗
    Primary completion Apr 1, 2026→Nov 1, 2028
    Study completion Apr 1, 2026→Nov 1, 2028
    + 4 other changes: verification date, description, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02308917
Collaborators
Children's Hospital of Eastern Ontario, British Columbia Children's Hospital, Alberta Children's Hospital, Stollery Children's Hospital, IWK Health Centre, Montreal Children's Hospital of the MUHC, St. Justine's Hospital, Health Sciences Centre, Winnipeg, Manitoba, Eastern Health, Children's Hospital of Western Ontario, McMaster Children's Hospital
Responsible party
Anne Griffiths (Division Head, Gastroenterology, Hepathology and Nutrition, The Hospital for Sick Children) — Principal investigator
First posted
Dec 5, 2014
Start date
Sep 2013
Primary completion
Nov 1, 2028 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Oct 9, 2026

Study contacts

Anne M Griffiths, MD, FRCPC
Contact
anne.griffiths@sickkids.ca
(416) 813-8757
Anne M Griffiths, MD, FRCPC
principal investigator · The Hospital for Sick Children

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion